Oxford BioTherapeutics Employee Directory
Biotechnology ResearchEngland, United Kingdom51-200 Employees
Oxford BioTherapeutics is a clinical-stage biotechnology company focused on oncology, developing immuno-oncology and antibody-drug conjugate therapies. Its lead asset, OBT076, is an ADC in Phase 1b trials designed to prime the immune response while directly targeting cancer cells. The firm relies on its OGAP Verify platform, built on a large cancer membrane proteomic database to identify oncology targets, with several programs in clinical development in the US and Europe. Headquartered in Oxford with operations in San Jose, CA and Morristown, NJ, it collaborates with major industry partners, including Boehringer Ingelheim, ImmunoGen and Kite Pharma. A notable development in June 2026 saw a Boehringer Ingelheim collaboration move a program into the clinic and advance the lead asset to Phase 3.